Photo from wikipedia
Deferring bladder augmentation (BA) may be desirable in a pediatric neurogenic bladder (NGB) with worsening compliance, but prior studies have questioned whether onabotulinum toxin A (BTX) demonstrates durable improvement in… Click to show full abstract
Deferring bladder augmentation (BA) may be desirable in a pediatric neurogenic bladder (NGB) with worsening compliance, but prior studies have questioned whether onabotulinum toxin A (BTX) demonstrates durable improvement in compliance. We present our overall experience with BTX and its role in mitigating the “at‐risk” NGB, as determined by urodynamic characteristics.
Keywords:
risk;
botulinum toxin;
augmentation;
bladder augmentation;
toxin patients
Journal Title: Neurourology and Urodynamics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Neurourology and Urodynamics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!